Compare ABM & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABM | IRON |
|---|---|---|
| Founded | 1909 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.0B |
| IPO Year | N/A | N/A |
| Metric | ABM | IRON |
|---|---|---|
| Price | $45.58 | $78.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $51.50 | ★ $110.08 |
| AVG Volume (30 Days) | ★ 695.0K | 537.0K |
| Earning Date | 03-11-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.59% | N/A |
| EPS Growth | ★ 102.34 | N/A |
| EPS | ★ 2.59 | N/A |
| Revenue | ★ $8,745,900,000.00 | N/A |
| Revenue This Year | $5.71 | N/A |
| Revenue Next Year | $1.99 | N/A |
| P/E Ratio | $17.29 | ★ N/A |
| Revenue Growth | ★ 4.62 | N/A |
| 52 Week Low | $40.00 | $30.82 |
| 52 Week High | $54.90 | $99.50 |
| Indicator | ABM | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 48.41 |
| Support Level | $44.59 | $74.42 |
| Resistance Level | $46.60 | $82.26 |
| Average True Range (ATR) | 0.93 | 3.70 |
| MACD | 0.06 | 0.83 |
| Stochastic Oscillator | 64.69 | 72.31 |
ABM Industries Inc is a provider of integrated facility solutions. It offers its solutions through five segments: Business and Industry, Manufacturing and Distribution, Education, Aviation and Technical solutions. The company derives the majority of its revenue from the business and industry segment, which encompasses janitorial, facilities engineering, and parking services for commercial real estate properties and sports and entertainment venues, hospitals, as well as vehicle maintenance and other services to rental car providers. The company mainly operates in the United States of America.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.